Soft tissue sarcomas (STS) are low-incidence, mesenchymal-derived tumors represented by more than 50 his to types. Despite the latest developments, the rates of patients developing recurrent and metastatic disease are high. Many of the mechanisms underlying STS are still unknown
{"title":"The Role of the Nucleotide-Excision Repair (NER) Pathway in Soft Tissue Sarcomas: A Review and a Focus on Its Potential as a Therapeutic Target","authors":"Pillozzi Serena, Scolari Federico, Pasqui Adriano, Boddi Anna, Fancelli Sara, Caliman Enrico, Palchetti Ilaria, Bernini Andrea, Petroni Giulia, Scoccianti Guido, Campanacci Domenico, Antonuzzo Lorenzo","doi":"10.31038/cst.2023824","DOIUrl":"https://doi.org/10.31038/cst.2023824","url":null,"abstract":"Soft tissue sarcomas (STS) are low-incidence, mesenchymal-derived tumors represented by more than 50 his to types. Despite the latest developments, the rates of patients developing recurrent and metastatic disease are high. Many of the mechanisms underlying STS are still unknown","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"458 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74286614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Integrins constitute a group of dimeric polypeptide chains that function as natural agonists of cell surface receptor-dependent cell activities.
整合素是一组二聚体多肽链，作为细胞表面受体依赖性细胞活性的天然激动剂。
{"title":"Alpha-Fetoprotein-derived Segments as Integrin Peptidomimetics for Potential Cancer Cell Targeting and Therapy: A Review and Commentary","authors":"G. Mizejewski","doi":"10.31038/cst.2023823","DOIUrl":"https://doi.org/10.31038/cst.2023823","url":null,"abstract":"Integrins constitute a group of dimeric polypeptide chains that function as natural agonists of cell surface receptor-dependent cell activities.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"60 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72496478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"TRG-High/ATM-Expressed/SIRT1-Absent Profile as Negative Prognostic Marker after Neoadjuvant Chemotherapy for Gastric Cancer","authors":"","doi":"10.31038/cst.2023822","DOIUrl":"https://doi.org/10.31038/cst.2023822","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79897588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Significant of Molecular Genotyping Over Serological Phenotyping Techniques in Determination of Blood Group Systems among Multiple Transfused Patients and Blood Donors to Prevent Alloimmunization: A Review Article","authors":"","doi":"10.31038/cst.2023821","DOIUrl":"https://doi.org/10.31038/cst.2023821","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74100487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Demographic and Clinicopathological Evaluation of Colorectal Adenocarcinoma in Bangladesh at a Tertiary Level Hospital","authors":"","doi":"10.31038/cst.2023811","DOIUrl":"https://doi.org/10.31038/cst.2023811","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"140 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76391425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ambivalent and Conjectural-Synovial Sarcoma","authors":"","doi":"10.31038/cst.2022734","DOIUrl":"https://doi.org/10.31038/cst.2022734","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88369451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Burzynski, Gregory S. Burzynski, T. Janicki, S. Beenken
Rationale: Glioblastoma (GBM), which accounts for 48% of all malignant central nervous system (CNS) tumors and 57% of gliomas, has a very poor prognosis. Patients with recurrent/persistent GBM after standard therapy usually die within six months. The case of an adult female with a recurrent/ persistent GBM is presented here to detail/discuss the efficacy of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of this disease. Objectives: This patient was treated at the Burzynski Clinic (BC), as a Compassionate Exemption (CE) according to the Phase II Protocol, BT-20, which utilized ANP therapy in the treatment of patients with GBMs. ANP therapy was delivered via subclavian catheter and infusion pump and then by mouth. Tumor response was measured by sequential magnetic resonance imaging (MRI) of the brain utilizing gadolinium enhancement. Findings: This patient was diagnosed with GBM of the right temporoparietal region in May 1997, at age 45, and underwent two surgical resections, radiation therapy (RT), and gamma knife ablation elsewhere. At age 46 years and eight months, she presented to the BC with recurrent/ persistent disease. She complained of weakness, dizziness, short-term memory loss, and nausea. She had difficulty speaking and walked with assistance due to discoordination and left-sided weakness. Baseline brain MRI at the BC revealed a measurable enhancing nodule in the surgical bed. ANP therapy was initiated in August 1998 and the patient achieved a complete response (CR) within five months. Now, 24 years later, the patient is doing well and showing no evidence of tumor recurrence. Conclusions: The utilization of ANP therapy to obtain a cure in a patient with recurrent/persistent GBM is presented. We conclude that ANP therapy is an attractive therapeutic option for adults with a GBM who are ineligible for or refuse standard therapy or demonstrate recurrent/persistent disease after standard therapy. We present here the successful use of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of recurrent/persistent GBM in a 46 year and eight-month-old female, initially diagnosed at age 45 and treated with gross total resection, radiation therapy (RT), gamma knife ablation of recurrent tumor, and subsequent right lobectomy elsewhere. We also present the use of targeted therapy in the treatment of GBM, including our own preliminary results.
{"title":"Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-free Survival in a 45-Year-Old Female Treated with Antineoplastons (Successful Treatment of Glioblastoma with Antineoplastons)","authors":"S. Burzynski, Gregory S. Burzynski, T. Janicki, S. Beenken","doi":"10.31038/cst.2022733","DOIUrl":"https://doi.org/10.31038/cst.2022733","url":null,"abstract":"Rationale: Glioblastoma (GBM), which accounts for 48% of all malignant central nervous system (CNS) tumors and 57% of gliomas, has a very poor prognosis. Patients with recurrent/persistent GBM after standard therapy usually die within six months. The case of an adult female with a recurrent/ persistent GBM is presented here to detail/discuss the efficacy of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of this disease. Objectives: This patient was treated at the Burzynski Clinic (BC), as a Compassionate Exemption (CE) according to the Phase II Protocol, BT-20, which utilized ANP therapy in the treatment of patients with GBMs. ANP therapy was delivered via subclavian catheter and infusion pump and then by mouth. Tumor response was measured by sequential magnetic resonance imaging (MRI) of the brain utilizing gadolinium enhancement. Findings: This patient was diagnosed with GBM of the right temporoparietal region in May 1997, at age 45, and underwent two surgical resections, radiation therapy (RT), and gamma knife ablation elsewhere. At age 46 years and eight months, she presented to the BC with recurrent/ persistent disease. She complained of weakness, dizziness, short-term memory loss, and nausea. She had difficulty speaking and walked with assistance due to discoordination and left-sided weakness. Baseline brain MRI at the BC revealed a measurable enhancing nodule in the surgical bed. ANP therapy was initiated in August 1998 and the patient achieved a complete response (CR) within five months. Now, 24 years later, the patient is doing well and showing no evidence of tumor recurrence. Conclusions: The utilization of ANP therapy to obtain a cure in a patient with recurrent/persistent GBM is presented. We conclude that ANP therapy is an attractive therapeutic option for adults with a GBM who are ineligible for or refuse standard therapy or demonstrate recurrent/persistent disease after standard therapy. We present here the successful use of ANP therapy (Antineoplaston A10 {Atengenal} and Antineoplaston AS2-1 {Astugenal}) in the treatment of recurrent/persistent GBM in a 46 year and eight-month-old female, initially diagnosed at age 45 and treated with gross total resection, radiation therapy (RT), gamma knife ablation of recurrent tumor, and subsequent right lobectomy elsewhere. We also present the use of targeted therapy in the treatment of GBM, including our own preliminary results.","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"149 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87546666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Continuation of Temozolomide Chemotherapy in a Glioblastoma Patient Post Resolution of COVID-19 Pneumonia","authors":"Anonymous","doi":"10.31038/cst.2022732","DOIUrl":"https://doi.org/10.31038/cst.2022732","url":null,"abstract":"","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84639539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renata Carolina Schlögel de Freitas, Renata de Souza-Silva, G. Vigo, L. Oliveira
The elaboration of the care plan for patients with terminal cancer must be based on a careful evaluation of clinical, bioethical and prognostic elements. The prognostic assessment can lead to the improvement of treatment strategies and support the planning of care and the efficient use of available resources, helping to minimize the risks of under treatment or excessive and futile treatments, especially in the phase close to death [1]. In the hospital setting, it is common for patients with terminal cancer to receive inadequate and ineffective care, with no provision for palliative care and pain relief. Even in a reality of scarce resources, there is an unnecessary use of invasive and high-tech methods, focused on trying to cure, which are unable to treat the most prevalent symptoms of the disease, prolonging suffering and pain [2].
{"title":"Assistance to Patients with Terminal Cancer in the Last 30 Days Prior to Death: Differences in the Care of the Usual Health Care Units and a Palliative Care Unit","authors":"Renata Carolina Schlögel de Freitas, Renata de Souza-Silva, G. Vigo, L. Oliveira","doi":"10.31038/cst.2022731","DOIUrl":"https://doi.org/10.31038/cst.2022731","url":null,"abstract":"The elaboration of the care plan for patients with terminal cancer must be based on a careful evaluation of clinical, bioethical and prognostic elements. The prognostic assessment can lead to the improvement of treatment strategies and support the planning of care and the efficient use of available resources, helping to minimize the risks of under treatment or excessive and futile treatments, especially in the phase close to death [1]. In the hospital setting, it is common for patients with terminal cancer to receive inadequate and ineffective care, with no provision for palliative care and pain relief. Even in a reality of scarce resources, there is an unnecessary use of invasive and high-tech methods, focused on trying to cure, which are unable to treat the most prevalent symptoms of the disease, prolonging suffering and pain [2].","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73707403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
phosphatase level were high in blood respectively 151 U/L and 493 U/l show in Figure 1. It indicates liver injury and cirrhosis. The AFP test indicates correlation with Hepatocellular carcinoma. The AFP level in patient was 6101 ng/ml and normal values were 0.1 – 10. Higher level of AFP indicates that HCC have positive relation with AFP to proliferate cancer. The test formed by fully automated state of the Art analyzer Beckman Coulter
{"title":"Role of Alpha Fetoprotein in Hepatocellular Carcinoma","authors":"Short Commentary, Muhammad Waqar Mazhar","doi":"10.31038/cst.2022723","DOIUrl":"https://doi.org/10.31038/cst.2022723","url":null,"abstract":"phosphatase level were high in blood respectively 151 U/L and 493 U/l show in Figure 1. It indicates liver injury and cirrhosis. The AFP test indicates correlation with Hepatocellular carcinoma. The AFP level in patient was 6101 ng/ml and normal values were 0.1 – 10. Higher level of AFP indicates that HCC have positive relation with AFP to proliferate cancer. The test formed by fully automated state of the Art analyzer Beckman Coulter","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"155 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86312261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：